Clinical trials: Alopecia Totalis
Alopecia Areata
Plaquenil for Alopecia Areata, Alopecia Totalis
Alopecia areata is an autoimmune condition resulting in hair loss and complete baldness (alopecia totalis). Published evidence says that it is mediated by T-lymphocytes.
- Trial name
- NCT00176982
- Testing
- Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hordinsky, Maria K., MD
Alopecia Areata
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.
- Trial name
- NCT02553330
- Testing
- Ruxolitinib Phosphate Cream
- Where
- 18 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Alopecia
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or Alopecia Totalis (AT) in adult subjects.
- Trial name
- NCT03594227
- Testing
- ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose)
- Where
- 25 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia Areata, Alopecia Totalis
Alopecia Areata Registry
Alopecia areata is the loss of hair in patches that can proceed to loss of all hair (alopecia totalis or universalis). The purpose of the registry is to collect patient information and blood samples from people with alopecia…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Autoimmune Hair Loss
- Trial name
- NAAR (NCT00069589)
- Where
- 5 sites in United States
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Alopecia Areata
Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
The goal of this clinical research study is to find the most effective dose of Targretin® (bexarotene) Gel 1% that can be given to patients as a treatment for alopecia areata.
- Trial name
- NCT00063076
- Testing
- Targretin Gel 1%
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center